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Quantitative Nuclear Proteomics Identifies
mTOR Regulation of DNA Damage
Response*□S
Sricharan Bandhakavi‡§, Young-Mi Kim‡§, Seung-Hyun Ro‡, Hongwei Xie‡,
Getiria Onsongo¶, Chang-Bong Jun‡, Do-Hyung Kim‡, and Timothy J. Griffin‡**
Cellular nutritional and energy status regulates a wide
range of nuclear processes important for cell growth,
survival, and metabolic homeostasis. Mammalian target
of rapamycin (mTOR) plays a key role in the cellular
responses to nutrients. However, the nuclear processes
governed by mTOR have not been clearly defined. Using
isobaric peptide tagging coupled with linear ion trap
mass spectrometry, we performed quantitative pro-
teomics analysis to identify nuclear processes in human
cells under control of mTOR. Within 3 h of inhibiting
mTOR with rapamycin in HeLa cells, we observed down-
regulation of nuclear abundance of many proteins in-
volved in translation and RNA modification. Unexpect-
edly, mTOR inhibition also down-regulated several
proteins functioning in chromosomal integrity and up-
regulated those involved in DNA damage responses
(DDRs) such as 53BP1. Consistent with these proteomic
changes and DDR activation, mTOR inhibition enhanced
interaction between 53BP1 and p53 and increased phos-
phorylation of ataxia telangiectasia mutated (ATM) ki-
nase substrates. ATM substrate phosphorylation was
also induced by inhibiting protein synthesis and sup-
pressed by inhibiting proteasomal activity, suggesting
that mTOR inhibition reduces steady-state (abundance)
levels of proteins that function in cellular pathways of
DDR activation. Finally, rapamycin-induced changes led
to increased survival after radiation exposure in HeLa
cells. These findings reveal a novel functional link be-
tween mTOR and DDR pathways in the nucleus po-
tentially operating as a survival mechanism against
unfavorable growth conditions. Molecular & Cellular
Proteomics 9:403–414, 2010.
Eukaryotic cells coordinately regulate molecular processes
in distinct subcellular compartments for growth and survival in
response to nutritional status and environmental stress. A
crucial integrator/coordinator for these cellular responses is
mTOR,1 a nutrient-responsive protein kinase belonging to the
phosphatidylinositol kinase-related kinase family (1). mTOR,
as a downstream element of the insulin/IGF-1-phosphoinosit-
ide 3-kinase-Akt pathway, plays an important role in the reg-
ulation of a variety of cellular processes in response to nutri-
ent and growth factor signals (1, 2). mTOR is mainly known for
its regulation of translation and protein synthesis, and it is also
involved in the regulation of diverse cellular and biological
processes such as cell cycle progression, actin cytoskeleton
rearrangement, transcription, autophagy, and development
(1, 2). Despite the pervasive role of mTOR in different cellular
functions, its ability to coordinately regulate diverse pro-
cesses in distinct cellular compartments, particularly those
occurring in the nucleus of mammalian cells, remains poorly
defined.
There has been growing evidence that TOR regulates di-
verse processes in the nucleus. In Saccharomyces cerevisiae,
TOR regulates the nucleocytoplasmic shuttling of several
transcription factors (1, 3). TOR complex 1, TORC1, itself
undergoes translocation to the nucleus and interacts with
chromatin-modifying factors within ribosomal RNA and sub-
telomeric loci to regulate the expression of ribosomal RNAs
and proteins and amino acid transporters (4). Microarray anal-
yses in Drosophila and mammalian cells revealed a key role
for TOR in regulating the expression of nuclear proteins in-
volved in cell growth (5–7). mTOR, like the yeast TOR1/2,
undergoes nucleocytoplasmic shuttling, and the nuclear lo-
calization was shown to be important to phosphorylate down-
stream substrates, such as S6K and 4E-BP1 (8, 9). A recent
study showed that nuclear mTOR interacts with the promy-
elocytic leukemia tumor suppressor under hypoxic conditions
to down-regulate mTOR signaling and neoangiogenesis in
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mouse and human tumors (10). mTOR also controls nuclear
localization of a few transcriptional regulators involved in cel-
lular stress responses and rRNA expression (9, 11–13).
Although these studies have indicated important roles for
mTOR in the regulation of nuclear events, the diversity of
nuclear functions under its control and how they are coor-
dinated with other roles of mTOR remain poorly understood.
Elucidating these functions would benefit from system-wide
analysis, such as mass spectrometry-based quantitative
proteomics, which has particular value for identifying post-
transcriptional changes that are not predicted using geno-
mics/transcriptomics methods (14–16). Maturing protein
preparation methods and mass spectrometry instrumenta-
tion (17), combined with subcellular fractionation, have
made possible discoveries of important regulatory events in
organelles within cells. However, such methods have not
yet been applied to studies on nutrient and mTOR regulation
of nuclear or other subcellular events.
In this study, we sought to profile nuclear proteins regulated
by mTOR using a recently developed method that combines
the robustness of an LTQ linear ion trap mass spectrometer
operated in pulsed Q dissociation (PQD) mode with isobaric
peptide labeling using the iTRAQ reagent (18). Our analysis
identified 48 proteins whose abundance in the nucleus is
altered by rapamycin in HeLa cells. Independent validation
confirmed that mTOR regulates nuclear abundance of pro-
teins involved in protein synthesis, RNA modification, and,
unexpectedly, chromosomal integrity and DNA damage re-
sponses (DDRs). Consistent with these proteomic changes,
downstream analysis determined that rapamycin or mTOR
knockdown activates ataxia telangiectasia mutated (ATM)/
DDR signaling. Rapamycin-induced ATM activation was mim-
icked by inhibition of protein synthesis and suppressed by
inhibition of proteasomal function. Finally, we identified that
the rapamycin-induced changes are important for cell survival
upon exposure to DNA-damaging conditions, such as ionizing
radiation (IR). Our results demonstrate the value of subcellular
quantitative proteomics for unraveling post-transcriptional
regulation and identifying novel mTOR functions within a
complex subcellular compartment.
EXPERIMENTAL PROCEDURES
Isolation of Nuclear and Cytoplasmic Fractions—Purified nuclei
were obtained from HeLa cells treated with rapamycin or vehicle for
3 h. Cells were harvested by trypsin; washed in PBS, low salt buffer
(buffer A: 10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM NaCl, 0.5 mM
DTT); and allowed to swell in buffer A supplemented with protease
inhibitor mixture (Roche Applied Science) for 15 min. Prior to homog-
enization, Nonidet P-40 was added to a final concentration of 0.3%,
and cells were lysed in a prechilled Dounce homogenizer with 20
strokes using a tight pestle. This mixture was centrifuged at 228  g
to obtain a crude nuclear pellet and cytoplasmic supernatant. The
nuclear pellet was resuspended in low sucrose buffer containing 0.3
M sucrose, 10 mM HEPES, pH 7.9, 5 mM MgCl2, 10 mM NaCl and
layered over 3 volumes of the same buffer supplemented to 1.8 M
sucrose followed by centrifugation at 25,000  g for 35 min. The
highly pure nuclear pellet was extracted with buffer A supplemented
with 0.42 M NaCl, 0.3 M sucrose, 0.5% Triton X-100 twice, and the
extracted protein was processed for proteomics analysis.
iTRAQ Labeling and Proteomics Analysis—Nuclear protein sam-
ples were acetone-precipitated and dissolved in iTRAQ dissolution
buffer. 100 g of protein from each sample was trypsinized, labeled
with iTRAQ reagents 114 (non-rapamycin treated sample) and 115
(rapamycin-treated sample). Labeled peptides were pooled and frac-
tionated by strong cation exchange (SCX) HPLC. 45 SCX fractions
were collected and analyzed using optimized collision energy settings
on an LTQ instrument (Thermo Scientific) using pulsed Q dissociation
(LTQ-PQD) as described (18).
Protein Identification and Quantification—Obtained MS/MS spec-
tra were searched using SEQUEST (19) (Bioworks version 3.2,
Thermo Finnigan, San Jose, CA) against a non-redundant human
protein sequence database from the European Bioinformatics Insti-
tute (ipi.HUMAN.v3.18.fasta containing 62,000 entries). This database
was chosen because it is manually curated to minimize protein
redundancy due to identical protein sequences appearing under
different accession codes. A reversed sequence version of the
same database was appended to the end of the forward version for
the purpose of false positive rate estimation (20). Search parame-
ters included static mass shift (144.0 Da) for the N terminus and
lysine due to modification with the iTRAQ reagent. Differential
amino acid mass shifts for oxidized methionine (16 Da) were also
included. Precursor peptide mass tolerance was 2.0 Da with
partial tryptic specificity. Fragment ion tolerance was set at 1.0 Da.
The search results were validated using the peptide validation
program PeptideProphet (21), which assigns a comprehensive
probability (p) score from 0 to 1 to each peptide sequence match
based on its SEQUEST scores (Xcorr, Cn, Sp, and RSp) and additional
information, including mass difference between the precursor ion and
the assigned peptide and the number of tryptic termini. The peptide
sequence match results were organized and interpreted using the soft-
ware tool Interact (22), allowing up to two missed cleavage for identified
peptides. Peptide matches were filtered using a p score threshold of
0.92 for all data sets, ensuring an estimated false positive rate below 1%
calculated by reversed database searching. Relative abundance ratios
for each identified protein were calculated as described previously (18).
iTRAQ ratios of individual proteins were normalized by dividing each
ratio by the average -fold change (2.1) calculated across all quantified
proteins in the data set.
To report the minimum set of protein sequences in our proteomic
catalogue that adequately accounts for all matched peptides, we
analyzed all matched peptide sequences for redundant inclusion in
multiple proteins in our sequence database. Proteins identified from
at least one non-redundant peptide sequence were retained in our
catalogue. For proteins identified from redundant peptides, we re-
tained those proteins in our catalogue only if the redundant proteins
matched to a closely related isoform of the same protein in the
database as determined by manual inspection. Proteins identified
from redundant peptides that matched to different proteins entirely
were removed.
Antibodies, Chemicals, and Cell Lines—The antibodies used were
as follows. Anti-mTOR (sc-1549), anti-p53 (sc-6243), anti-Ku70 (sc-
9033), and anti-ATM (sc-7230) antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). Anti-S6K1 (9202), anti-phos-
pho-S6K1 Thr-389 (9205), anti-phospho-53BP1 Ser-25/29 (2674),
anti-phospho-ATM and Rad3-related kinase (ATR) Ser-428 (2853),
anti-AMPK (2532), anti-phospho-AMPK Thr-172 (2531S), and anti-
phospho-p53 Ser-15 (9284) were from Cell Signaling Technology
(Danvers, MA). Anti-53BP1 (A300-272A), anti-eIF3S8 (A300–376A),
anti-MDC1 (A300-051A), anti-RPL7A (A300-749A), anti-SMC2 (A300-
058A), anti-NCAPD3 (A300-604A), anti-NUP98 (A301-786A), and anti-
mTOR Regulation of DNA Damage Identified by Proteomics
404 Molecular & Cellular Proteomics 9.2
H2AX (A300-082A) antibodies were from Bethyl Laboratories (Mont-
gomery, TX). Antibodies against fibrillarin (ab4566), U1A (ab40689),
nucleophosmin (ab10530), Histone H1.0 (ab11079), and SNF2L2/
hBRM (ab15597) were from Abcam (Cambridge, MA). Anti-53BP1
(DR1003), anti-phospho-H2AX Ser-139 (DR1017), and anti-p53
(OP03) were from Calbiochem. Antibodies against telomerase reverse
transcriptase (TERT) (MA3-16571 and NB110-89471) were purchased
from Affinity BioReagents (Golden, CO) and Novus (Littleton, CO),
respectively. Antibodies against valosin-containing protein (612182)
and actin (612656) were purchased from BD Biosciences. Secondary
antibodies coupled to AlexaFluor 488 and AlexaFluor 647 were ob-
tained from Invitrogen. Rapamycin (Calbiochem), cycloheximide, and
MG132 were used at 50 nM, 50 M, and 10 M, respectively. Leucine
amino acid starvation was done by rinsing cells in leucine-free RPMI
1640 medium twice and incubating in leucine-free RPMI 1640 me-
dium supplemented with or without 52 g/ml leucine for 2 h (23). All
other reagents were purchased from Sigma unless indicated other-
wise. ATM cell lines were a generous gift from Dr. E. Hendrickson’s
laboratory at the University of Minnesota. HeLa, HEK293T, and WI38
cell lines were obtained from the ATCC (Manassas, VA).
Cell Culture and Transfection—HeLa, HEK293T, and WI38 cells
were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen)
supplemented with 10% fetal bovine serum, penicillin, and strepto-
mycin at 37 °C in 5% CO2. ATM wild type and null lymphoblast cells
were grown in RPMI 1640 medium (Invitrogen) containing 15% fetal
calf serum. Cells were transfected with DNA constructs to express
green fluorescent protein (GFP) fusion protein or short hairpin RNA
plasmids using FuGENE 6 (Roche Applied Science) following the
manufacturer’s protocol. The siRNAs were transiently transfected into
HeLa cells using jetSITM-ENDO (Polyplus transfection). siRNA-trans-
fected cells were harvested 2 or 3 days post-transfection for Western
blotting and confocal microscopic analysis. The target sequences for
mTOR and S6K1 are 5-aaccctgcctttgtcatgcct-3 and 5-cagctac-
catccacacaaata-3, respectively.
DNA Construction—The DNA constructs for GST- or Myc-tagged
recombinant proteins were generated by PCR amplification of cDNA
clones obtained from Open Biosystems or the Kazusa Institute in
Japan. Amplified DNAs were cloned into pEGFP-C3 or N1 vectors
(Clontech) or prk-myc.
Immunoprecipitation and Western Blotting—Total nuclear extracts
for Western blotting were prepared by boiling isolated nuclei in SDS
sample buffer, whereas cytoplasmic fractions were concentrated us-
ing Amicon Ultrafree concentrators and adjusted to the same volume
in SDS sample buffer. The same volumes of nuclear and cytoplasmic
fractions were loaded for Western blot analysis unless indicated
otherwise. Total cell lysates were prepared in RIPA buffer (12.5 mM
NaPO4, pH 7.2, 2 mM EDTA, 50 mM NaF, 1.25% Nonidet P-40, 1.25%
SDS, 0.1 mM DTT). For immunoprecipitations, HeLa cells were lysed
in buffer 1 (20 mM TrisHCl, pH 8.0, 0.4 M NaCl, 1 mM EDTA, 0.5%
Nonidet P-40), and an equal volume of buffer 1 lacking NaCl was
added to cell lysates. Immunoprecipitates were isolated using anti-
p53 or anti-53BP1 antibodies and washed four times with buffer 1
wash buffer (20 mM TrisHCl, pH 8.0, 0.2 M NaCl, 1 mM EDTA, 0.5%
Nonidet P-40). Proteins were loaded onto Tris-glycine gels, trans-
ferred to PVDF membranes, and processed for Western blot analysis.
Quantitative Real Time RT-PCR Analysis—HeLa cells were treated
with rapamycin or methanol for the indicated periods of time (1, 2, 3,
and 6 h of treatment) and harvested. No significant effects on RNA
levels of tested genes were detected at 30 min of rapamycin treat-
ment (data not shown). RNA was isolated using TRIzol (Invitrogen),
and cDNA was reverse transcribed. Real time PCR analysis was
performed on a Roche Light Cycler 3.5 instrument using the FastStart
DNA MasterPlus SYBR Green I kit (Roche Applied Science). Primers
used for the PCRs are listed in supplemental Table 3. Cycle thresh-
olds for each gene were normalized to tubulin, and the results were
expressed as -fold changes with respect to those obtained with cells
treated with methanol as controls.
Confocal Microscopy—For immunofluorescence, HeLa cells
treated with rapamycin/vehicle for 3 h were fixed with 4% paraform-
aldehyde and blocked in a PBS buffer containing 0.1% saponin and
3% BSA. This was followed by incubating with primary antibodies and
subsequently with secondary antibodies coupled to AlexaFluor 488 or
AlexaFluor 647. TERT staining was performed as described previ-
ously (24). Cells were also stained with 4,6-diamidino-2-phenylindole
for the nucleus. Stained cells were mounted in Vectashield (Vector
Laboratories, Burlingame, CA), and images were acquired using an
Olympus FluoView 1000 IX2 inverted microscope.
Clonogenic Viability Assay—HeLa cells in 6-well plates seeded at
300 cells/well were preincubated for 0, 3, or 24 h with rapamycin (50
nM) or methanol and then irradiated at the indicated doses of IR. After
irradiation, cells were refreshed with new medium and maintained for
14 days in the absence of rapamycin. Cells were stained with crystal
violet, and the number of colonies on plates was counted. Three
experiments were conducted for each condition. Cell lysates were
prepared in RIPA buffer after cells were incubated in a 37 °C incuba-
tor for 90 min following radiation.
RESULTS
Quantitative Proteomics Analysis via iTRAQ Reagent Label-
ing and LTQ-PQD Identifies Rapamycin-regulated Nuclear
Proteome Changes—We used a quantitative mass spectro-
metric approach using iTRAQ reagent peptide labeling to
identify proteins whose abundance in the nucleus is altered by
rapamycin, a classical and specific inhibitor of mTOR function
(1, 2) (Fig. 1a). Rather than build a definitive catalogue of
nuclear proteins affected by rapamycin treatment, our goal
was to use quantitative proteomics as a first pass screen from
which we could obtain a list of proteins putatively regulated by
mTOR and generate new hypotheses for further testing via
biochemical and cell biological methods. Therefore, we car-
ried out a single quantitative proteomics analysis on highly
pure nuclei isolated from two groups of HeLa cells, one
treated with rapamycin and the other treated with methanol as
a control for 3 h. Isolated nuclei were determined to be mor-
phologically intact (by phase-contrast microscopy) and highly
pure (by Western blotting for nuclear and cytoplasmic marker
proteins) as shown in supplemental Fig. 1. Nuclear proteins
were trypsinized, labeled with iTRAQ stable isotope-encoded
reagents, pooled, and fractionated by SCX HPLC. The pep-
tide fractions were subsequently analyzed by microcapillary
reversed-phase LC-MS/MS on a linear ion trap (LTQ) instru-
ment operated in PQD mode using methods we have de-
scribed previously (18).
We obtained a catalogue of 503 proteins identified from two
or more unique peptides along with several hundred more
proteins identified by single peptide hits at an estimated false
positive rate below 1%. Based on our bioinformatics analysis
described below, we selected seven additional proteins iden-
tified by single hits, resulting in a final catalogue of 510 total
proteins. Supplemental Table 1 shows these proteins along
with all relevant identification information and iTRAQ reporter
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ion intensities. Quantification of the identified proteins was
accomplished using a previously described software pro-
gram, which automatically summed iTRAQ reporter ion inten-
sities derived from centroided MS/MS spectra matched to
each protein (18).
Protein ratios were normalized to the average ratio (2.1)
calculated across the entire set of proteins to correct for any
bias introduced in sample preparation and handling based on
the assumption that protein ratios should be centered around
unity. Based on previous observations of iTRAQ reagent data
on the LTQ, for normalizing our protein abundance ratios, we
did not include proteins that showed iTRAQ reporter ion in-
tensities that were below 100 counts as these provide lower
confidence quantitative ratios (25). Western blotting of several
rapamycin-affected proteins (Fig. 2) supported the corrected
ratios as being accurate. We defined proteins as being sig-
nificantly changed in abundance if they showed a normalized
-fold change of at least 2.0 or more as it was significantly
outside the calculated standard deviation (0.4) across the set
of quantified proteins.
With the goal of generating hypotheses for further testing,
we grouped our entire set of identified proteins using Ingenu-
ity Pathway analysis to reveal trends in the functional classes
of proteins affected by rapamycin treatment. Using the cri-
teria described above, 48 proteins were selected from our
proteomic data set that showed significant changes in their
abundance upon rapamycin treatment with most (39 of 48)
decreasing in their abundance (supplemental Table 2).
Based on their known functions, rapamycin-affected pro-
teins were classified into six functional groups (supplemen-
tal Table 2 and Fig. 1b): (i) DNA damage/repair (seven pro-
teins), (ii) chromosomal integrity (eight proteins), (iii) RNA
binding/modification (seven proteins), (iv) protein synthesis/
translation (12 proteins), (v) mitochondrial processes (three
proteins), and (vi) other/unknown functions (11 proteins).
Most of these proteins (41 of 48 proteins) were identified by
two distinct peptides or more. The remaining seven proteins
(53BP1, nucleophosmin (NPM), MDC1, FAM44a, NCAPD3,
polypyrimidine tract-binding protein 2 (PTBP2), and RPL7A)
were identified by a single peptide match. Supplemental
Fig. 2 shows the annotated MS/MS spectra matched to
these seven proteins. Representative members of DNA
damage/repair, chromosomal integrity, RNA binding/modi-
fication, and protein synthesis/translation functional cate-
gories and their -fold changes upon rapamycin treatment
are indicated in Fig. 1c.
To confirm the veracity of our proteomic findings overall,
abundance changes of selected, representative proteins from
each functional category, as well as six of the seven proteins
identified by single peptide matches, were independently val-
FIG. 1. Rapamycin induces abundance changes within nuclear proteome of HeLa cells. a, experimental design for quantitative
proteomics analysis. For additional details, see “Experimental Procedures.” b, functional classification of nuclear proteins that changed in
nuclear abundance 2-fold or more upon rapamycin treatment. c, normalized -fold changes in the levels of rapamycin-regulated proteins. The
labels w, endo, and gfp in parentheses indicate Western blotting, immunostaining of endogenous proteins, and GFP fluorescence microscopy,
respectively, which were used to validate mass spectrometry measurements.
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idated through use of immunofluorescence microscopy
and/or Western blotting (Fig. 2, a and b, and supplemental
Figs. 3–5). For all these proteins, the relative abundance levels
measured by immunofluorescence and/or Western blotting
were consistent with the quantitative proteomics results.
Among functional classes of affected proteins, a few in-
volved in protein synthesis/translation, such as eIF3S8 and
RPL7A, and RNA modification, such as PTBP1, might be
expected based on the known roles of mTOR (1, 2, 26).
Particularly, the decrease of PTBP1 and -2 is consistent with
a recent report that they are translocated to the cytoplasm
under amino acid starvation (a condition that inhibits mTOR
(1, 2)) and relocalized to the nucleus upon supplementation
with amino acids (a condition that activates mTOR (1, 2, 26).
Because PTBP1 and -2 reduction is predicted to increase
expression of their nuclearly localized paralog, regulator of
differentiation 1 (ROD1) (27), we tested for potential effect of
rapamycin on GFP fusion ROD1 levels. Indeed, we found that
rapamycin significantly increased ROD1 levels in the nucleus
(supplemental Fig. 4).
An unexpected finding from our proteomics analysis was
the effect of rapamycin on proteins involved in DNA modifi-
cation pathways that regulate DNA damage/repair and chro-
mosomal integrity. 15 of 48 affected proteins were involved in
these pathways (supplemental Table 2 and Fig. 1b). Inde-
pendent validation of 11 of these 15 proteins is shown in Fig.
2, a and b, confirming that rapamycin affected DNA modifi-
cation pathways regulated by these proteins. Up-regulated
proteins included substrates of the DNA damage signaling
kinases ATM kinase and ATR (28) (53BP1, FAM44a, and
MDC1) and other proteins implicated in DNA damage re-
sponses such as tankyrase 1-binding protein 1 (TNKS1BP1),
NPM, and NUP98 (29–31). This group also included the mul-
tifunctional protein scaffold attachment factor B2 (SAFB2),
which has been implicated in coupling transcriptional regula-
tion and cytoskeletal signaling with pre-mRNA splicing and
cellular proliferation (32, 33). Down-regulated proteins in-
cluded TERT (24), the global transcription activator SNF2L2
(34), and the chromatin condensin complex members (35)
condensing-2 complex subunit D3 (NCAPD3) and structural
maintenance of chromosomal protein 2 (SMC2), which are all
involved in chromosomal integrity (Fig. 2, a and b). We also
detected nuclear and cytoplasmic down-regulation of valosin-
containing protein (Fig. 2b, see the seventh panel from the
top), an Akt substrate involved in nuclear envelope recon-
struction, protein degradation pathways, and nuclear inclu-
sion body diseases (36).
Next, we tested the abundance level of mRNAs corre-
sponding to functionally distinct classes of rapamycin-sensi-
tive proteins. With the exception of TNKS1BP1, the remaining
proteins were unaffected in regard to the abundance level of
their corresponding mRNA transcripts (supplemental Fig. 6).
This includes the absence of a significant effect on TERT
mRNA (supplemental Fig. 6) or the telomeric RNA component
hTR (supplemental Fig. 7). Interestingly, previous studies
demonstrated that long term treatment with rapamycin re-
duced mRNA levels of TERT in distinct cell lines (37, 38); our
work indicates earlier reduction of TERT protein abundance in
HeLa cells that is independent of mRNA level changes. The
analysis of mRNA levels of multiple rapamycin-sensitive pro-
teins indicates significant post-transcriptional regulation in the
nucleus by rapamycin and illustrates the value of subcellular
quantitative proteomics in identifying such regulatory events.
mTOR Inhibition Activates DDR Pathways—To explain the
effect of rapamycin on proteins involved in DNA modification
FIG. 2. Independent validation of proteomic changes across
rapamycin-affected functional categories. a, validation of mass
spectrometric results performed by immunostaining of endogenous
(endo) or recombinant proteins (myc) or using GFP fluorescence (gfp)
of transiently expressed proteins. HeLa cells were stained using an-
tibody specific to the indicated proteins (endo) or transiently trans-
duced to express GFP-tagged proteins (gfp) and visualized by fluo-
rescence microscopy. b, validation of mass spectrometric results of
nuclear abundance changes in HeLa cells by Western blotting. HeLa
cell extracts were separated into cytoplasm (cyto) and nuclear (nuc)
fractions as described under “Experimental Procedures,” and their
cellular equivalents were loaded on SDS-PAGE prior to Western
blotting. S6K1 and fibrillarin levels were monitored for assessing
purity of cytoplasmic and nuclear fractions, respectively. VCP, valo-
sin-containing protein; snRNP, small nuclear ribonucleoprotein.
mTOR Regulation of DNA Damage Identified by Proteomics
Molecular & Cellular Proteomics 9.2 407
pathways, we considered the potential effect on cellular DDR
under these conditions. Initially, we focused on 53BP1 given
its known role as an early sensor of DNA damage (28). In-
creased nuclear accumulation of 53BP1 was apparent as
early as 30 min after rapamycin treatment (Fig. 3a). 53BP1
was not affected at its mRNA levels by rapamycin (supple-
mental Fig. 6). An increase of 53BP1 in nuclear fractions
coincided with a barely detectable decrease in cytoplasmic
fractions (Fig. 3b, top panel), whereas overall cellular levels
demonstrated no change (Fig. 3c, bottom panel). To test
whether rapamycin caused translocation of 53BP1 from the
cytoplasm to the nucleus, we concentrated cytoplasmic pro-
teins further and loaded increased protein amounts of cyto-
plasmic fractions and decreased protein amounts of nuclear
fractions (while still maintaining equal protein amounts for
cytoplasmic and nuclear fractions, respectively). Under these
conditions, rapamycin-induced translocation of 53BP1 was
evident (Fig. 3b, bottom panel). As part of a cellular DDR,
53BP1 cooperates with p53 (39, 40). Hence, we tested for
potential effects of rapamycin on the 53BP1/p53 interaction
via immunoprecipitation. Consistent with DDR activation, ra-
pamycin enhanced association of 53BP1 with p53 (Fig. 3c).
The related kinases ATM and ATR are central to cellular
DDR as they promote DNA repair and cell survival by phos-
phorylation of substrate proteins (28). As a measure of ATM/
ATR activation, we monitored the effect of mTOR inhibition on
phosphorylation of ATM/ATR substrates, 53BP1Ser-25/29 and
H2AXSer-139 as well as formation of 53BP1 nuclear foci. Ra-
pamycin and mTOR knockdown enhanced ATM/ATR-specific
phosphorylation of 53BP1Ser-25/29 and H2AXSer-139 in HeLa
FIG. 3. mTOR inhibition activates cellular DNA damage response pathways. a, time course of the effects of rapamycin on nuclear (nu)
and cytoplasmic (cyt) levels of 53BP1 in HeLa cells. -Fold changes for relative intensities of 53BP1 bands are given below the 53BP1 blot. b,
nuclear and cytoplasmic levels of 53BP1 upon rapamycin treatment. The amount of cytoplasmic protein loaded was increased and nuclear
protein amounts were proportionally decreased to test for translocation of 53BP1 by rapamycin. c, rapamycin enhances interaction between
53BP1 and p53. Immunoprecipitates (IP) were isolated from HeLa cells using either anti-p53 or anti-53BP1 antibody, and the amounts of
associated 53BP1 and p53, respectively, were analyzed by Western blotting. d and e, rapamycin (3 h) and mTOR knockdown enhance
phosphorylation of 53BP1 and H2AX in HeLa cells. f, rapamycin and mTOR silencing induced an increase in 53BP1 foci formation. HeLa cells
treated with rapamycin/vehicle for 3 h or transduced with mTOR/control siRNA were monitored for the number of 53BP1 foci microscopically;
error bars indicate calculated standard deviation from independent experiments. g, rapamycin induces phosphorylation of 53BP1 and H2AX
in ATM/ cells within 3 h but not in ATM/ cells. h, rapamycin (rapa) induced H2AX phosphorylation in WI38 and 293T cells. i, rapamycin
inhibits extraction of nuclear Ku70 by salt treatment in HeLa nuclear preparations. HeLa cells treated with rapamycin/methanol for 3 h were
processed for Ku70 or histone H1 (control) extractability from nuclear fractions under increasing NaCl concentrations as indicated. Numbers
below blots indicate relative band intensities as determined by the Image J software. exp., exposure; sh, short hairpin.
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cells (Fig. 3, d and e). mTOR inhibition and rapamycin treat-
ment also produced a modest increase in the number of
53BP1 nuclear foci (Fig. 3f). Together, these results support
the notion that mTOR inhibition activates DDR in HeLa cells.
The ability of rapamycin to stimulate phosphorylation of
53BP1 and H2AX was seen in ATM/ but not in ATM/
lymphoblastic cells (Fig. 3g). Furthermore, rapamycin did not
have any effect on ATR autophosphorylation in HeLa cells,
implying that mTOR inhibition specifically activated ATM but
not ATR signaling (supplemental Fig. 8). H2AXSer-139 phos-
phorylation was stimulated by rapamycin in at least two other
cell lines, WI38 and 293T cells (Fig. 3h).
As a further test of DDR activation, we examined effects of
rapamycin on recruitment of the DNA repair factor Ku70.
ATM-dependent and -independent signaling causes recruit-
ment of repair factors such as Ku70 to sites of DNA damage
(41); this pool of Ku is relatively resistant to biochemical
extraction (30). Supporting an activation of Ku proteins, we
observed increased amounts of Ku70 extracted at higher
concentrations of salt (0.4 M NaCl, 0.5 M NaCl, and pellet
fractions) upon rapamycin treatment (Fig. 3i).
Collectively, the preceding results indicate that mTOR
inhibition activated multiple steps of cellular DDR. Impor-
tantly, DDR-related phenotypes were apparent as early as
30 min (53BP1 phosphorylation; supplemental Fig. 9a) to
1.5 h (-H2AX phosphorylation; supplemental Fig. 9b) after
rapamycin treatment, suggesting that these are unlikely to
be related to potential effects of rapamycin on cell cycle
progression.
Rapamycin-induced Activation of DDR Is Mimicked by
Treatments That Inhibit Protein Synthesis and Suppressed by
Proteasomal Inhibition—Next, we sought to understand how
mTOR inhibition caused cellular DDR activation. Given that
mTOR is a critical regulator of protein synthesis and transla-
tion, we investigated whether attenuating this cellular function
might activate DDR/ATM signaling. Consistent with activated
ATM signaling, a short pulse of treatment with the global
protein synthesis inhibitor cycloheximide increased phos-
phorylation of 53BP1Ser-25/29 and H2AXSer-139 in HeLa cells
(Fig. 4a). Similar results were also seen with amino acid star-
vation (supplemental Fig. 10), a treatment that inhibits mTOR
and protein synthesis/translation (2, 42). Thus, protein synthe-
sis inhibition is sufficient for cellular DDR activation, suggest-
ing a potential basis for rapamycin-induced DDR. Attenuating
protein synthesis would be expected to reduce overall protein
levels (with proteins having relatively short half-lives, i.e. in-
trinsically unstable proteins being especially affected), includ-
ing those that function to maintain chromosomal structure
and/or operate within pathways of cellular DDR activation.
Interestingly, our proteomics analysis identified nuclear
proteins involved in chromosomal integrity to be down-regu-
lated upon rapamycin treatment (SNF2L2, TERT, NCAPD3,
and SMC2; Fig. 1c) with no correlated effects on their mRNA
levels (supplemental Fig. 6). Given the role of chromosomal



































1 0.91 0.47 0.82
1 0.90 0.43 0.57
1 0.87 0.51 0.94
1 1.30 0.53 1.50












































FIG. 4. Rapamycin-induced changes are mimicked by protein synthesis inhibition. a, effect of protein synthesis inhibitor cycloheximide
(CHX; 50 M, 90 min) on -H2AX and 53BP1 phosphorylation in HeLa cells. b, order of appearance of phosphorylation of 53BP1 and H2AX
versus down-regulation of rapamycin-sensitive chromosomal integrity maintenance proteins upon cycloheximide treatment. Numbers indicate
-fold changes in band intensities relative to those at no cycloheximide. c, effect of proteasomal inhibitor MG132 on rapamycin-induced
phosphorylation of H2AX and down-regulation of the chromosomal integrity proteins. d, effect of mTOR knockdown, S6K1 knockdown, and
24 h of rapamycin treatment on levels of SNF2L2, TERT, NCAPD3, SMC2, and -H2AX.
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structure in the regulation of DDR pathways (43, 44) and the
functions that the above mentioned set of proteins plays in
maintaining chromosomal structure/integrity, one possibility
is that their loss specifically triggered DDR upon rapamycin
treatment.
To test whether the specific loss of rapamycin-sensitive
chromosomal integrity proteins could activate DDR, we ini-
tially monitored the effect of a time course of cycloheximide
treatment (Fig. 4b) on the levels of SNF2L2, TERT, NCAPD3,
and SMC2 and their correlation with DDR activation (-H2AX
and 53BP1 phosphorylation). SNF2L2, TERT, NCAPD3, and
SMC2 decreased in overall abundance upon incubation of
HeLa cells with cycloheximide for 1.5 h or longer; additionally,
their decrease correlated well with increased phosphorylation
of H2AXSer-139. However, 53BP1 phosphorylation occurred
(by 30 min of cycloheximide treatment) substantially before
the reduction in levels of SNF2L2, TERT, NCAPD3, and
SMC2. Similarly, rapamycin-induced 53BP1 phosphorylation
was apparent within 30 min of drug treatment, a time point at
which there was no significant effect on the levels of SNF2L2,
TERT, NCAPD3, and SMC2 (supplemental Fig. 9a). Thus, it
appears unlikely that the specific reduction of the above men-
tioned chromosomal integrity proteins triggered DDR activa-
tion upon rapamycin treatment/mTOR inhibition. However,
based on the known functions of these proteins, their reduced
levels might play a role in sustaining DDR.
As an alternative, we tested whether stabilizing overall pro-
tein levels by proteasomal inhibition might affect rapamycin-
induced phosphorylation of H2AX. As shown in Fig. 4c, co-
treatment of cells with rapamycin and the proteasomal
inhibitor MG132 suppressed H2AX phosphorylation. MG132
treatment also stabilized the levels of rapamycin-sensitive
chromosomal integrity proteins, demonstrating that their
steady-state levels are under proteasomal control. Thus, sta-
bilization of proteins that might be intrinsically unstable (i.e.
sensitive to attenuated protein synthesis/translation that fol-
lows mTOR inhibition) or potentially destabilized by mTOR
inhibition is sufficient to suppress rapamycin-induced DDR
activation. We anticipate that at least some of the rapamycin-
sensitive proteins that are stabilized by proteasomal inhibition
function in pathways of cellular DDR activation. Further work
is necessary to identify rapamycin/protein synthesis-sensitive
molecular candidates regulating DDR activation.
A major downstream effector of mTOR and a regulator of
protein translation is S6K1 (1, 45). To further test for an
involvement of protein synthesis inhibition in mTOR regulation
of DDR, we tested the effect of S6K1 knockdown on steady-
state levels of the nuclear proteins SNF2L2, TERT, NCAPD3,
and SMC2 and the phosphorylation of H2AX. In contrast to
what was seen upon prolonged rapamycin treatment or
mTOR knockdown, S6K1 knockdown reduced the levels of
SNF2L2 and SMC2 but not of TERT and NCAPD3 (Fig. 4d).
Amino acid starvation, by contrast, did not affect levels of
SNF2L2 and SMC2 (supplemental Fig. 10). Stable knockdown
of either mTOR or S6K1 increased H2AXSer-139 phosphoryla-
tion, although this increase may be due to increases in the
total levels of H2AX (Fig. 4d). Similar results were obtained
from transient siRNA-based knockdown of mTOR or S6K1
(supplemental Fig. 11). Based on these findings, we infer that
S6K1 has a partial role in mediating the effects of mTOR
inhibition on cellular DDR activation.
Rapamcyin Pretreatment Enhances Radioresistance in
HeLa Cells—Cells with activated DDR (either because of pre-
exposure to stress or activating mutations) have a higher
resistance to radiation or genotoxic stress (43, 46). Therefore,
we tested for potential effects of rapamycin on cellular resis-
tance to IR. Co-treatment of HeLa cells with rapamycin and IR
had essentially no effect on cellular resistance compared with
IR alone (Fig. 5a). In contrast, pretreatment of cells with rapa-
mycin for 3 or 24 h prior to IR enhanced their survival rates,
indicating a radioresistance effect (Fig. 5, b and c). A potential
basis for this result is that rapamycin enhanced the ability of
HeLa cells to repair DNA damage. Supporting this notion, we
found that after pretreatment of cells with rapamycin for 3 or
24 h they accumulated lower levels of -H2AX upon subse-
quent exposure to increasing dosages of IR at 2.5 Gy or
higher (Fig. 5d). This contrasts with the observation at lower
doses of IR or in the absence of IR wherein rapamycin pre-
treatment increased -H2AX levels. Thus, rapamycin exerts a
relatively modest effect on ATM activation compared with 2.5
Gy of IR (see also Fig. 3f showing substantially lower 53BP1
foci formation by rapamycin treatment versus 2.5 Gy of IR).
However, rapamycin pretreatment activated a sufficiently
broad DDR that enhances the ability of cells to reduce the
effect of genotoxic stress on cell survival.
DISCUSSION
We have applied mass spectrometry-based proteomics to
study mTOR regulation of the nuclear proteome, providing a
panoramic snapshot of mTOR functions in the nucleus. Inter-
estingly, several of the validated protein changes induced by
rapamycin were not mirrored by changes in their correspond-
ing mRNA levels with the only exception being TNKS1BP1
(supplemental Fig. 6). Thus, we identified several mTOR-reg-
ulated post-transcriptional events that would not have been
detectable by transcriptomics or genomics approaches.
Additionally, our results provide a demonstration of the
effectiveness of combining iTRAQ reagent stable isotope la-
beling and analysis using an LTQ linear ion trap mass spec-
trometer operated in PQD mode for a large scale quantitative
proteomics study. We first described proof-of-principle stud-
ies demonstrating the potential for this method, which offers
the powerful combination of multiplexed stable isotope label-
ing with a highly sensitive mass spectrometer (18, 25). Given
the relatively small number of studies to date using the ion
trap instrumentation for iTRAQ studies (47, 48), our results
provide an important demonstration of the effectiveness of
this method for large scale analysis within a complex sample,
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supporting its value as a general tool for quantitative proteom-
ics studies.
Our quantitative proteomics analysis revealed new nuclear
functions regulated by mTOR. Specifically, the down-regula-
tion of proteins involved in chromosomal integrity and an
up-regulation of those involved in DDR upon rapamycin treat-
ment pointed to a role for mTOR in regulating these functions
in the cell. Given these unexpected findings, we focused on
further characterizing this connection. Collectively, our ob-
served effects on proteins involved in chromosomal integrity,
ATM signaling, and the salt extractability of Ku70 (Figs. 1–3)
suggest that mTOR inhibition putatively affects chromosomal
structure and/or proteins that operate in pathways of cellular
DDR activation. Several groups have documented that altered
chromosomal structure is sufficient for activation of DDR
pathways (43, 44). Using pulsed field electrophoresis, we
were unable to detect direct DNA damage upon rapamycin
treatment (data not shown), suggesting that the main effect of
rapamycin/mTOR inhibition was on DDR activation rather
than causing significant levels of DNA damage. Importantly,
the effect mTOR inhibition on DDR activation is not a transient
stress response but initiated early (supplemental Fig. 9) and
sustained for at least 24 h of rapamycin treatment or longer
(when mTOR is knocked down; Fig. 4d). Because chromo-
somal structure is an important determinant of gene expres-
sion, these effects could also explain how mTOR inhibition
could potentially alter overall gene expression patterns and
cellular processes in response to nutrients (5–7). In line with our
results, rapamycin-sensitive and -insensitive branches of TOR
signaling have been implicated in regulating chromosomal
structure/functions in budding and fission yeasts (49, 50).
We suggest that activation of ATM by rapamycin depends
on the steady-state level of currently unidentified critical pro-
teins that function in pathways of cellular DDR activation. This
is supported by our observation that proteasomal inhibition
suppressed rapamycin-induced DDR, whereas translational
attenuation by nutrient (amino acid starvation), molecular
(S6K1 knockdown), and pharmacological (cycloheximide)
treatments activated DDR. Based on the excellent agreement
with cycloheximide treatment, we favor the notion that mTOR
signaling regulates ATM via its effect on cellular protein syn-
thesis machinery. However, potential regulation of proteaso-
mal degradation pathways upon mTOR inhibition toward sim-
ilar proteins also could contribute to ATM activation.
Additional investigation is necessary to discriminate between
these possibilities.
We also tested whether rapamycin treatment might acti-
vate AMPK, which in turn could lead to DDR activation.
However, both short and long term treatment with rapamy-
cin had no detectable effect on AMPK activation/phos-
phorylation, arguing against this possibility (supplemental
Fig. 12).
Interestingly, all proteins up-regulated by rapamycin within
the nucleus grouped within the functional category of DDR
proteins. Among DDR proteins, we observed that rapamycin
altered the ratio of abundance of 53BP1 between the cyto-
plasm and nucleus (Fig. 3a) but did not affect overall cellular
levels of this protein. This implies that mammalian cells have
FIG. 5. Pretreatment with rapamycin enhances resistance of HeLa cells to radiation. HeLa cells treated with rapamycin/vehicle were
exposed immediately to increasing doses of ionizing radiation (a) or after 3 (b) or 24 h (c) of pretreatment with rapamycin. Cell viability was
measured as described under “Experimental Procedures.” The effective doses of Gy to reduce the number of cell colonies by 50% were 3.44 
0.43 (rapamycin) and 3.75  0.32 Gy (rapamycin) for co-treatment, 3.32  0.24 (rapamycin) and 4.88  0.26 Gy (rapamycin) for 3-h
pretreatment, and 2.79  0.19 (rapamycin) and 4.39  0.21 Gy (rapamycin) for 24-h pretreatment. d, rapamycin-induced resistance to
radiation (when cells were pretreated for 3 or 24 h) correlated with reduced accumulation of -H2AX in response to ionizing radiation. Numbers
below the blots show -fold change in protein levels as determined by the Image J software. exp., exposure.
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evolved mechanisms other than translation through which
they transmit cytoplasmic signals of mTOR inhibition to the
nucleus, reminiscent of the role played by yeast TOR in af-
fecting nucleocytoplasmic relocalization events (1, 3). In con-
trast to 53BP1, subcellular relocalization is unlikely to account
for increased abundance of TNKS1BP1 or the exclusively
nuclear DDR proteins such as MDC1, NUP98, and NPM. One
possibility is that rapamycin specifically stabilizes these pro-
teins via inhibiting their degradation by the proteasome. How-
ever, this appears unlikely given the generally catabolic ef-
fects of rapamycin (1, 2) and its ability to enhance, rather than
impede, proteasomal degradation of specific proteins (51, 52).
An alternative possibility is that rapamycin enhances transla-
tion of transcripts corresponding to these DDR proteins via
internal ribosome entry site/highly structured 5-UTRs. Sup-
porting such a possibility, the MFOLD algorithm (53) predicted
strong secondary structures within the 5-UTR of NPM1,
NUP98, and MDC1 with G values of 48.7, 148.3, and
170 kcal, respectively. TNKS1BP1 mRNA levels also in-
creased upon rapamycin treatment, and supporting its poten-
tial for alternative translation, the 5-UTR contains predicted
strong secondary structure(s) (G  81.5 kcal according to
the MFOLD algorithm). These collective results point to a
combination of mechanisms being likely involved in causing
increased nuclear accumulation of DDR proteins upon rapa-
mycin treatment.
The increased radioresistance of HeLa cells due to rapamycin
indicates a positive effect of rapamycin on resistance to DNA
damage (Fig. 5). The radioresistance was only observed with
rapamycin pretreatment but not co-treatment with ionizing ra-
diation, implying a time lag for signal amplification of the rapa-
mycin-induced cellular response. Consistent with our observed
inverse correlation between mTOR activity and radioresistance,
previous studies demonstrated that mouse embryonic fibro-
blast cells deficient for the mTOR inhibitors TSC1 and TSC2 had
a higher sensitivity to genotoxic agents, and rapamycin sup-
pressed the sensitivity (54). However, this is not apparently a
universal phenotype because variable effects of rapamycin/
TOR inhibition on radio- or chemoresistance have been re-
ported in different cell types and organisms (50, 55, 56). The
relative balance between apoptotic induction and activation of
cell survival and DDR pathways could represent a potential
basis for these differences. Further work is necessary to eluci-
date the molecular basis for distinct effects of mTOR inhibition
on different cell types. Regardless, the possibility that rapamy-
cin/mTOR inhibition enhances radioresistance of some cancer
cells has important implications for cancer treatments that com-
bine genotoxic agents with mTOR inhibitors.
Collectively, our findings have potentially broad implica-
tions given that protein synthesis/TOR is emerging as an
important determinant of aging and cancer (57, 58). Of note,
recent studies indicated that defects in genome stability can
trigger survival response similar to what is seen under calorie
restriction or inhibition of insulin-like growth factor-1 signaling
(59). These findings lie on the same line as our result that
rapamycin-induced DDR activation enhanced survivability
against DNA-damaging stresses. Several studies using model
organisms revealed a positive effect of TOR inhibition or
stress (at a moderate level) on lifespan extension (27). Our
findings point to a possibility that rapamycin-induced activa-
tion of DDR or other changes in the nucleus may contribute to
regulation of lifespan.
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